Belantamab Mafodotin, Pomalidomide,and Dexamethasone in Multiple Myeloma
Dimopoulos M, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
Meletios Athanasios Dimopoulos, M.D., Meral Beksac, M.D., Ludek Pour, M.D.,
Sosana Delimpasi, M.D., Vladimir Vorobyev, M.D., Hang Quach, M.D.,
Ivan Spicka, C.Sc., Jakub Radocha, M.D., Ph.D., Pawel Robak, M.D., Ph.D.,
Kihyun Kim, M.D., Michele Cavo, M.D., Kazuhito Suzuki, M.D., Ph.D.,
Kristin Morris, Pharm.D., Farrah Pompilus, Ph.D., Amy Phillips‑Jones, M.Sc.,
Xiaoou L. Zhou, M.D., Ph.D., Giulia Fulci, Ph.D., Neal Sule, M.B., B.S., M.D.,
Brandon E. Kremer, M.D., Ph.D., Joanna Opalinska, M.D., Ph.D.,
María‑Victoria Mateos, M.D., Ph.D., and Suzanne Trudel, M.D.,
for the DREAMM-8 Investigators
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University
of Athens (M.A.D.), and General Hospital Evangelismos (S.D.) — both in Athens; the Department of Hematology, Ankara Liv
Hospital, Istinye University, Ankara, Turkey (M.B.); the Department of Internal Medicine, Hematology, and Oncology, University Hospital
Brno, Brno (L.P.), the First Faculty of Medicine, Charles University, and General Hospital, Prague (I.S.), and the Fourth Department
of Internal Medicine–Hematology, University Hospital Hradec Králové, and Faculty of Medicine in Hradec Králové, Charles University,
Hradec Králové (J.R.) — all in the Czech Republic; Leningrad Regional Clinical Hospital, Saint Petersburg, Russia (V.V.); the University
of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia (H.Q.); Medical University of Lodz, Łódź, Poland (P.R.); Sungkyunkwan
University and Samsung Medical Center, Seoul, South Korea (K.K.); IRCCS Azienda Ospedaliero–Universitaria di Bologna,
Seràgnoli Institute of Hematology, and Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (M.C.); the
Division of Clinical Oncology–Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo (K.S.); GSK,
Durham, NC (K.M.); GSK, Philadelphia (F.P.), and GSK, Collegeville (N.S., B.E.K., J.O.) — both in Pennsylvania; GSK, Stevenage,
United Kingdom (A.P.-J.); GSK, Waltham, MA (X.L.Z., G.F.); the Hematology Department, Cancer Research Center–Instituto de Investigación
Biomédica de Salamanca, University Hospital of Salamanca, Salamanca, Spain (M.-V.M.); and the Department of Medical
Oncology and Hematology, Princess Margaret Cancer Center, Toronto (S.T.)